UCI International’s Bankruptcy
June 08, 2016
On June 1, 2016, UCI International LLC and certain of its affiliates (“UCI”) filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. UCI, a subsidiary of Rank Group, is a motor vehicle parts and systems business with approximately $469 million in funded indebtedness at the timing of its bankruptcy filing, including approximately $69 million in drawn borrowings under its senior secured asset‑based revolving credit facility (the “ABL Facility”), under which the two lenders are Credit Suisse AG, Cayman Islands Branch (“Credit Suisse”) and an affiliate of Rank Group. UCI also has $400 million in unsecured notes. UCI’s bankruptcy filing followed a missed $17.25 million interest payment on the unsecured notes in February 2016 and efforts at an out‑of‑court resolution.
Cravath represents Credit Suisse as lender and administrative agent of the ABL facility in connection with the Chapter 11 cases.
The Cravath team representing Credit Suisse in connection with UCI’s restructuring and court proceedings includes partners Paul H. Zumbro and Omid H. Nasab, practice area attorney Jin Hee Kim and associates Gregory D. Beaton, Sharon Freiman, Brendan C. Benedict, Samuel P. Niles and Sean M. Linnehan. Summer associates Matthew Weiner and Alex B. Weiss are also working on these matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 1992, Yale CollegeDistinction in Major, cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2006, Columbia Law SchoolHarlan Fiske Stone Scholar
-
A.B., 2002, Duke University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
July 13, 2026
Boluda Towage’s €2.45 Billion Term Loan and Revolving Credit Facilities
Cravath represented the agent, mandated lead arrangers and lenders in connection with Boluda Towage’s €2.15 billion (equivalent) term loan facility and €300 million multi‑currency revolving credit facility. The proceeds will be used towards refinancing certain existing credit facilities and for general corporate purposes. Boluda Towage is a leading maritime services operator. The transaction closed on June 30, 2026.
Deals & Cases
April 06, 2026
Versigent’s $1.35 Billion Credit Facilities and $1.6 Billion High‑Yield Senior Notes Offering in Connection with Aptiv PLC’s Spin‑Off of Versigent
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.
Deals & Cases
February 20, 2026
First Solar’s $1.5 Billion Revolving Credit Facility
Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
